Commit Biologics is pioneering the use of complement activation to eliminate target cells in cancer and autoimmune disease. Its first-in-class BiCE™ platform creates bispecific complement engagers that boost complement-mediated cytotoxicity of monoclonal antibodies.
Location: Aarhus, Denmark
Board director: Janine Schuurman - Roderick Verhelst
Board observer: Nico Vandervelpen
Website: